Full Text View
Tabular View
No Study Results Posted
Related Studies
Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer
This study is ongoing, but not recruiting participants.
Study NCT00004879   Information provided by National Cancer Institute (NCI)
First Received: March 7, 2000   Last Updated: February 6, 2009   History of Changes

March 7, 2000
February 6, 2009
April 2000
 
 
 
Complete list of historical versions of study NCT00004879 on ClinicalTrials.gov Archive Site
 
 
 
Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer
An Open Label, Multiple Dose, Dose-Rising Clinical Trial of the Safety of ABX-EGF in Patients With Renal, Prostate, Pancreatic, Non-Small-Cell Lung, Colorectal, or Esophageal Cancer

RATIONALE: Monoclonal antibodies such as ABX-EGF can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.

PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody ABX-EGF in treating patients who have either renal (kidney), prostate, pancreatic, non-small cell lung, colon, rectal, esophageal, or gastroesophageal junction cancer.

OBJECTIVES:

  • Determine the safety of monoclonal antibody ABX-EGF in patients with renal, prostate, pancreatic, non-small cell lung, colorectal, esophageal, or gastroesophageal junction cancer.
  • Determine the pharmacokinetics and the dose-response relationship of this drug in this patient population.
  • Evaluate the clinical effect of this drug in this patient population.

OUTLINE: This is an open-label, dose-escalation, multicenter study.

Patients receive monoclonal antibody ABX-EGF IV over 1 hour once weekly on weeks 0-3* (enrollment for the weekly dosing schedule completed as of 4/21/03 [with the exception of patients undergoing full pharmacokinetic analyses, described below]) OR once every 2 weeks on weeks 0, 2, 4, and 6* OR once every 3 weeks on weeks 0, 3, 6, and 9*. Patients undergoing full pharmacokinetic analyses receive a loading dose on week 0 and the subsequent 3 doses on weeks 3-5.

NOTE: *All patients receive a total of 4 doses.

Cohorts of 2-8 patients receive escalating doses of monoclonal antibody ABX-EGF until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 or 3 patients experience dose-limiting toxicity.

Patients are followed every 2 weeks for 5 weeks.

PROJECTED ACCRUAL: A total of 76 patients will be accrued for this study within approximately 14 months.

Phase I
Interventional
Treatment, Open Label
  • Colorectal Cancer
  • Esophageal Cancer
  • Kidney Cancer
  • Lung Cancer
  • Pancreatic Cancer
  • Prostate Cancer
Biological: panitumumab
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Active, not recruiting
 
 
 

DISEASE CHARACTERISTICS:

  • Histologically confirmed diagnosis of 1 of the following:

    • Renal cell cancer (RCC)

      • Prior nephrectomy required
    • Prostate cancer

      • Failed prior primary therapy (e.g., surgery, radiotherapy, or chemotherapy)
      • Failed prior hormonal therapy (e.g., antiandrogen, luteinizing hormone-releasing hormone inhibitor, or orchiectomy)
    • Pancreatic cancer

      • Failed at least 1 prior standard therapy regimen for unresectable metastatic disease
    • Non-small cell lung cancer

      • Failed at least 1 prior standard therapy regimen for unresectable metastatic disease
    • Colorectal cancer

      • Received 1 or more prior chemotherapy regimen(s) for advanced metastatic disease
    • Esophageal cancer

      • Failed prior primary therapy (e.g., surgery, radiotherapy, or chemotherapy)
    • Gastroesophageal junction cancer
  • Evaluable disease
  • Epidermal growth factor receptor overexpression

    • Tumor tissue must yield the sum of 1+, 2+, or 3+ staining in at least 10% of evaluated tumor cells
  • No uncontrolled brain metastases
  • No evidence of disease progression or regression after a 30-day washout period

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance status:

  • Karnofsky 70-100% OR
  • ECOG 0-1

Life expectancy:

  • Not specified

Hematopoietic:

  • Absolute neutrophil count greater than 1,000/mm^3
  • Platelet count greater than 100,000/mm^3

Hepatic:

  • AST/ALT no greater than 2 times upper limit of normal (ULN) (3 times ULN for liver metastases)
  • Alkaline phosphatase no greater than 2 times ULN (3 times ULN for liver metastases)

Renal:

  • Creatinine less than 2.2 mg/dL
  • NCI renal toxicity no greater than grade 2
  • No hypercalcemia (antihypercalcemic therapy allowed)

Cardiovascular:

  • Ejection fraction at least 45% by MUGA
  • No abnormal ECG or MUGA
  • No myocardial infarction within the past year

Pulmonary:

  • No abnormal chest x-ray
  • FEV_1 greater than 50% of predicted

Other:

  • No known allergy to ingredients of study drug
  • No known allergy to Staphylococcus aureus Protein A
  • HIV negative
  • No chronic medical or psychiatric condition that would preclude study compliance
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 2 months after study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • At least 30 days since prior biologic therapy (e.g., antibodies, cytokines, or co-stimulatory pathway inhibitors)
  • No other concurrent biologic therapy

Chemotherapy:

  • See Disease Characteristics
  • At least 6 weeks since prior chemotherapy and recovered
  • No prior chemotherapy for RCC
  • No prior anthracyclines
  • No concurrent chemotherapy

Endocrine therapy:

  • See Disease Characteristics
  • Concurrent steroids allowed
  • Concurrent hormonal therapy allowed

Radiotherapy:

  • See Disease Characteristics
  • No prior mediastinal radiotherapy
  • No concurrent radiotherapy

Surgery:

  • See Disease Characteristics
  • Recovered from any recent prior surgery

Other:

  • At least 30 days since prior investigational drug or device
  • At least 30 days since prior systemic therapy
  • No other concurrent investigational drugs
  • No other concurrent systemic agents or cancer therapy
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00004879
 
CDR0000067539, UCLA-9906078, ABX-EG-9901, UCLA-9906078-04B, NCI-G00-1673
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Principal Investigator: Arie Belldegrun, MD, FACS Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
August 2004

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP